Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 18 April 2022, 15:03 HKT/SGT
Share:
    

Source: NEC Corporation
Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine

OSAKA, Japan and TOKYO, Japan, Apr 18, 2022 - (JCN Newswire) - Shionogi & Co., Ltd. and NEC Corporation, today announced the execution of a strategic research collaboration agreement for the development of a novel hepatitis B therapeutic vaccine. NEC OncoImmunity, an NEC subsidiary that specializes in artificial intelligence-driven biotechnology, is also participating in this research collaboration.

Hepatitis B is a potentially life-threatening liver disease caused by the hepatitis B virus (HBV). Chronic infection with HBV results in a high risk of death from cirrhosis and liver cancer. About 300 million people are living with chronic hepatitis B infection worldwide, and hepatitis B resulted in an estimated 820,000 deaths in 20191. Although the widespread use of hepatitis B vaccines in infants has considerably reduced the incidence of new chronic HBV infections under the age of 5, the number of new infections by other routes continues to increase2.

Interferon (IFN) and nucleotide analog therapy are currently used in the treatment of hepatitis B. However, treatment with IFN has a high frequency of side effects, and nucleotide analog therapy has a high recurrence rate if treatment is interrupted, so it is necessary to take drugs for a lifetime3. Therefore, the unmet medical need for safe and highly effective drugs that can finally achieve a complete cure for hepatitis B is high.

Isao Teshirogi, President & CEO, Shionogi said:
"Shionogi has been engaged in the research and development of infectious diseases for over 60 years. As a leading infectious disease company, we are taking on the challenge of protecting people from the threat of infectious diseases and realizing total care. One company, and even the entire pharmaceutical industry on its own, can only go so far in dealing with a global pandemic like COVID-19. We will further enhance our contribution to global health by integrating NEC's AI technologies while leveraging our strengths."

Nobuhiro Endo, Chairman of the Board, NEC Corporation said:
"NEC is committed to our vision of 'Orchestrating a brighter world,' and we are delighted to collaborate with Shionogi to realize this vision through the development of novel treatments for patients. The innovative AI technologies of the NEC Group have the potential to overcome several challenges in what is usually a long and labor-intensive drug discovery process. Through this new partnership with Shionogi, a recognized leader in the field of infectious disease, we aim to maximize the contribution of our AI to accelerate the pace of drug discovery, and thereby to contribute to society."

By fusing Shionogi's drug discovery capability, focused on the infectious disease field, with NEC's expertise in artificial intelligence (AI), the companies will accelerate the progress toward a new therapeutic vaccine. Going forward, the companies will continue to actively expand such joint research into other infectious diseases where unmet medical needs remain.

About Shionogi & Co., Ltd.

Shionogi is committed to "Protect people worldwide from the threat of infectious diseases" as our key focus. We are not limiting ourselves to the research and development of therapeutic medications, but are also focused on the total care of infectious disease, through detection and forecast, prevention, diagnosis, and treating exacerbations, as well as the infection itself. For more information, please visit https://www.shionogi.com/global/en/.

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.

About NEC OncoImmunity AS

NEC OncoImmunity AS is an AI-driven biotechnology company that has developed proprietary machine learning-based software which addresses the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy, in addition to infectious disease vaccines. The AI technology can be used to identify optimal neoantigen targets for truly personalized cancer vaccines and cell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy. For more information, visit NEC OncoImmunity AS at https://www.oncoimmunity.com/.


Topic: Press release summary
Source: NEC Corporation

Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


NEC Corporation Links

http://www.nec.com

https://www.facebook.com/nec.global/

https://twitter.com/NEC_corp

https://www.youtube.com/user/NECglobalOfficial

https://www.linkedin.com/company/nec/

NEC Corporation
Dec 19, 2024 11:02 HKT/SGT
NEC Completes new Asia Pacific submarine cable
Dec 18, 2024 16:12 HKT/SGT
NEC Receives Telecom Review's Global Excellence Award for Innovative Telecom B2B/ Enterprise Network Solutions
Dec 12, 2024 15:27 HKT/SGT
NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1, an AI-Driven Personalized Oral Cancer Vaccine, at ESMO Immuno-Oncology Congress 2024
Dec 9, 2024 13:06 HKT/SGT
NEC begins sale of 100G QSFP28 ZR4 single-fiber bi-directional optical transceiver
Nov 29, 2024 14:27 HKT/SGT
JAL and NEC Test AI-Powered Carry-On Baggage Analysis Solution
Nov 20, 2024 14:30 HKT/SGT
Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center
Nov 18, 2024 16:29 HKT/SGT
World's First Successful Trial of Quantum Tokens Created Using Quantum Technology
Nov 13, 2024 11:05 HKT/SGT
Predictive Heart Monitoring Startup, GPx, Secures New Investment From NEC X; Joins Elev X! Boost Venture Studio Program
Nov 13, 2024 10:16 HKT/SGT
NEC receives order for next-generation supercomputer system from Japan's National Institutes for Quantum Science and Technology and National Institute for Fusion Science
Nov 12, 2024 18:25 HKT/SGT
NEC participates in COP29 climate change conference
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: